Progyny (NASDAQ:PGNY) Research Coverage Started at Wells Fargo & Company

Wells Fargo & Company began coverage on shares of Progyny (NASDAQ:PGNY) in a research report sent to investors on Wednesday morning,Benzinga reports. The firm issued an overweight rating and a $37.00 price target on the stock.

Several other analysts have also recently commented on PGNY. Weiss Ratings cut shares of Progyny from a “hold (c+)” rating to a “hold (c)” rating in a research note on Monday, August 31st. Citizens Jmp boosted their price target on shares of Progyny from $31.00 to $33.00 and gave the stock a “market outperform” rating in a research note on Tuesday, September 8th. JPMorgan Chase & Co. increased their price target on shares of Progyny from $27.00 to $30.00 and gave the stock a “neutral” rating in a report on Friday, August 21st. Canaccord Genuity Group set a $35.00 price objective on shares of Progyny in a research report on Friday, August 7th. Finally, KeyCorp lifted their price objective on Progyny from $30.00 to $35.00 and gave the company an “overweight” rating in a report on Monday, July 13th. One analyst has rated the stock with a Strong Buy rating, nine have given a Buy rating and three have assigned a Hold rating to the stock. Based on data from MarketBeat, Progyny presently has an average rating of “Moderate Buy” and a consensus target price of $34.36.

Progyny Price Performance

Progyny stock opened at $25.23 on Wednesday. Progyny has a 12 month low of $16.10 and a 12 month high of $33.06. The business has a 50 day simple moving average of $27.13 and a 200-day simple moving average of $24.80. The stock has a market capitalization of $1.94 billion, a PE ratio of 27.42, a price-to-earnings-growth ratio of 1.72 and a beta of 1.02.

Progyny (NASDAQ:PGNY) last issued its quarterly earnings results on Thursday, August 6th. The company reported $0.55 earnings per share for the quarter, topping the consensus estimate of $0.33 by $0.22. The firm had revenue of $350.51 million during the quarter, compared to the consensus estimate of $349.05 million. Progyny had a return on equity of 15.98% and a net margin of 6.00%.The company’s revenue for the quarter was up 5.3% on a year-over-year basis. During the same period last year, the company earned $0.19 earnings per share. Progyny has set its Q3 2026 guidance at 0.500-0.520 EPS and its FY 2026 guidance at 2.040-2.100 EPS. As a group, equities research analysts anticipate that Progyny will post 1.25 EPS for the current year.

Insider Buying and Selling at Progyny

In other news, Director Kevin K. Gordon sold 11,500 shares of the stock in a transaction dated Thursday, September 10th. The shares were sold at an average price of $27.94, for a total value of $321,310.00. Following the completion of the transaction, the director owned 6,792 shares in the company, valued at $189,768.48. This trade represents a 62.87% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, EVP Allison Swartz sold 3,903 shares of the firm’s stock in a transaction dated Wednesday, September 23rd. The shares were sold at an average price of $26.10, for a total transaction of $101,868.30. Following the completion of the sale, the executive vice president owned 75,816 shares of the company’s stock, valued at $1,978,797.60. This trade represents a 4.90% decrease in their position. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. 9.90% of the stock is currently owned by insiders.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently added to or reduced their stakes in the stock. Hsbc Holdings PLC acquired a new stake in shares of Progyny during the 2nd quarter valued at approximately $760,000. AWM Investment Company Inc. purchased a new stake in shares of Progyny during the 2nd quarter worth approximately $6,343,000. Bank of America Corp DE grew its holdings in shares of Progyny by 75.3% in the 1st quarter. Bank of America Corp DE now owns 1,190,996 shares of the company’s stock worth $20,223,000 after acquiring an additional 511,609 shares during the period. Royal Bank of Canada grew its holdings in shares of Progyny by 98.0% in the 1st quarter. Royal Bank of Canada now owns 218,434 shares of the company’s stock worth $3,709,000 after acquiring an additional 108,137 shares during the period. Finally, Bank of New York Mellon Corp acquired a new stake in shares of Progyny in the 2nd quarter worth approximately $11,932,000. 94.93% of the stock is currently owned by institutional investors and hedge funds.

Progyny Company Profile

Progyny, Inc (NASDAQ: PGNY) is a fertility and family-building benefits company that helps employers provide reproductive health services to their employees. Its platform is designed to support individuals and families navigating fertility treatment, preservation, adoption, surrogacy and related family-building needs.

The company offers an integrated benefits solution that combines personalized care navigation with access to a network of fertility specialists and treatment providers. Progyny also provides pharmacy benefits through Progyny Rx, helping members obtain and manage medications commonly used in fertility treatments.

Progyny primarily serves employer-sponsored benefit programs in the United States.